Vir Biotechnology (VIR) Osake Kurssi

Vir Biotechnology Inc is primarily active in the biotechnology industry.

Vir Biotechnology Inc has several main competitors in the market. Some of the notable competitors of Vir Biotechnology Inc include Gilead Sciences Inc, Moderna Inc, and Regeneron Pharmaceuticals Inc. These companies operate in the field of biotechnology and pharmaceuticals, specializing in developing innovative therapies, treatments, and vaccines. With their focus on advancing biomedical research and developing breakthrough solutions, the competitive landscape for Vir Biotechnology Inc remains intense. However, Vir Biotechnology Inc strives to stay at the forefront of the industry by leveraging its expertise and partnerships to address global health challenges and deliver value to its stakeholders.

Vir Biotechnology Inc. is a renowned company with an impressive history and background. Founded in 2016, Vir Biotechnology is a clinical-stage immunology company focused on developing therapeutic solutions for severe infectious diseases. The company is committed to utilizing cutting-edge technologies to address global health challenges. Vir Biotechnology has established strategic partnerships with world-leading institutions and has a diverse portfolio of innovative treatments. With its relentless dedication to scientific excellence and unwavering commitment to public health, Vir Biotechnology Inc. has gained significant recognition and continues to be at the forefront of advancing breakthrough treatments for infectious diseases worldwide.

Vir Biotechnology Inc has achieved several significant milestones in its journey. The company successfully completed its initial public offering (IPO) in October 2019, raising substantial capital to support its research and development efforts. Vir Biotechnology has also formed multiple strategic collaborations with renowned pharmaceutical companies, including Gilead Sciences and GlaxoSmithKline, to advance its pipeline of innovative therapies. Furthermore, Vir Biotechnology received fast-track designation from the U.S. Food and Drug Administration (FDA) for its potential therapy for hepatitis B virus infection. These accomplishments demonstrate Vir Biotechnology's commitment to progress and innovation in the field of biotechnology.

Vir Biotechnology Inc is primarily present in the United States.

Vir Biotechnology Inc is a leading biotechnology company with a strong focus on innovation and scientific excellence. The company's core values revolve around integrity, collaboration, and a commitment to improving patient health. Vir Biotechnology Inc believes in leveraging cutting-edge technologies to develop novel therapeutic solutions for the most challenging infectious diseases. With a mission to address global health concerns, the company combines its extensive expertise in immunology and infectious diseases to create transformative treatments and preventive measures. Vir Biotechnology Inc's corporate philosophy centers around the belief that every patient deserves access to safe and effective therapies.

Analyytikot asettavat tällä hetkellä Vir Biotechnology-osakkeelle keskimääräisen tavoitehinnan 21,43 USD (mediaani: 20,00 USD), mikä merkitsee +89,6 % viimeisimpään hintaan verrattuna. Konsensus perustuu 13 analyytikkoarvioon.

Vir Biotechnology Analyytikkojen kursstavoitteet 2026

13 analyytikkoa arvioi tällä hetkellä Vir Biotechnology-osaketta: 12 suosittaa ostoa, 1 pitoa ja 0 myyntiä. Vuodelle 2026 analyytikot odottavat Vir Biotechnology-yhtiöltä 245,24 M USD liikevaihtoa ja −2,03 USD osakekohtaista tulosta.

Vir Biotechnology Analyytikkojen kursstavoitteet 2026

Nykyisellä valuuttakurssilla Vir Biotechnology-osake noteerataan hintaan 10,09 EUR (11,30 USD).

Vir Biotechnology-osake (VIR) on listattuna 1 pörssissä, muun muassa: NASDAQ (VIR).

Vir Biotechnology Inc. is a young biopharmaceutical company that focuses on combating infectious diseases. The company relies on a combination of scientific expertise, innovative technologies, and extensive partnerships to develop advanced therapies and vaccines against some of the world's most dangerous viruses. The company specializes in three main areas: infectious diseases, immunology, and oncology. In the field of infectious diseases, Vir Biotechnology focuses on developing drugs for serious viral infections such as HIV, hepatitis B, cytomegalovirus, and influenza. In the field of immunology, the company explores the mechanisms underlying the immune system to find new ways to treat autoimmune and inflammatory diseases. Additionally, Vir is working on developing cancer immunotherapies and personalized therapy approaches for the fight against cancer. The company works closely with a range of partners, including universities, research institutions, and biopharmaceutical companies. In 2020, Vir entered into a collaboration agreement with biotechnology company GSK to jointly develop antibodies against COVID-19. A key part of Vir Biotechnology's business model is research and development of new therapies and vaccines. The company heavily invests in its research facilities in San Francisco, California and Cambridge, United Kingdom to develop new technologies and solutions. Vir has already brought several products to market, including a new antibody preparation for the treatment of influenza and a personalized immunotherapy for cancer. Additionally, the company aims to develop a variety of products and technologies to combat infectious diseases, including viral vectors, RNA- and DNA-based therapies, and new immunotherapies. Vir Biotechnology's business model also includes a strong capital raising strategy. The company has already completed several funding rounds and successfully gone public to support its growth and advancement. In summary, Vir Biotechnology is an innovative biopharmaceutical company that is developing a wide range of products and technologies to combat infectious diseases, autoimmune diseases, and cancer. The company relies on scientific expertise, partnerships, and a strong capital raising strategy to promote the growth and development of its business. With a dedicated focus on research and development and a strong pipeline of products and therapies, Vir Biotechnology remains a key player in the fight against infectious diseases and other serious conditions. Vir Biotechnology Inc. is a young biopharmaceutical company that focuses on combating infectious diseases. The company relies on a combination of scientific expertise, innovative technologies, and extensive partnerships to develop advanced therapies and vaccines against some of the world's most dangerous viruses. The company specializes in three main areas: infectious diseases, immunology, and oncology. In the field of infectious diseases, Vir Biotechnology focuses on developing drugs for serious viral infections such as HIV, hepatitis B, cytomegalovirus, and influenza. In the field of immunology, the company explores the mechanisms underlying the immune system to find new ways to treat autoimmune and inflammatory diseases. Additionally, Vir is working on developing cancer immunotherapies and personalized therapy approaches for the fight against cancer. The company works closely with a range of partners, including universities, research institutions, and biopharmaceutical companies. In 2020, Vir entered into a collaboration agreement with biotechnology company GSK to jointly develop antibodies against COVID-19. A key part of Vir Biotechnology's business model is research and development of new therapies and vaccines. The company heavily invests in its research facilities in San Francisco, California and Cambridge, United Kingdom to develop new technologies and solutions. Vir has already brought several products to market, including a new antibody preparation for the treatment of influenza and a personalized immunotherapy for cancer. Additionally, the company aims to develop a variety of products and technologies to combat infectious diseases, including viral vectors, RNA- and DNA-based therapies, and new immunotherapies. Vir Biotechnology's business model also includes a strong capital raising strategy. The company has already completed several funding rounds and successfully gone public to support its growth and advancement. In summary, Vir Biotechnology is an innovative biopharmaceutical company that is developing a wide range of products and technologies to combat infectious diseases, autoimmune diseases, and cancer. The company relies on scientific expertise, partnerships, and a strong capital raising strategy to promote the growth and development of its business. With a dedicated focus on research and development and a strong pipeline of products and therapies, Vir Biotechnology remains a key player in the fight against infectious diseases and other serious conditions.

odotettu liikevaihto Vir Biotechnology on 245,24 M USD. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.

odotettu voitto Vir Biotechnology on −283,00 M USD. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.

Vir Biotechnology:n hinta-voitto-suhde (P/E) on tällä hetkellä −5,56. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan Vir Biotechnology-osakkeen arvostusta.

Vir Biotechnology:n hinta-myynti-suhde (P/S) on tällä hetkellä 6,42. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii Vir Biotechnology-osakkeen arvostuskennuslukuna.

Vir Biotechnology:n Eulpool-laatuscore on 3/10.

Vir Biotechnology:n ISIN on US92764N1028. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.

Vir Biotechnology:n WKN on A2PS0P. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.

Vir Biotechnology:n ticker on VIR. Tämä pörssinoteeraus käytetään Vir Biotechnology-osakkeiden kauppaan pörssissä.